Angiogenesis as a target for the treatment of ovarian cancer

D Shaw, A Clamp, GC Jayson - Current opinion in oncology, 2013 - journals.lww.com
Both the first-line trials stopped maintenance bevacizumab after 12 and 15 months,
respectively; yet, current data suggest that maintenance therapy should continue at least …
被引用次数：45 相关文章

[引用][C] Angiogenesis as a target for the treatment of ovarian cancer

D Shaw, A Clamp, GC Jayson - Current Opinion in Oncology, 2013 - cir.nii.ac.jp
Angiogenesis as a target for the treatment of ovarian cancer | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

Angiogenesis as a target for the treatment of ovarian cancer.

D Shaw, AR Clamp, GC Jayson - 2013 - christie.openrepository.com
Angiogenesis has been validated as a target in ovarian cancer through four randomized
trials that have reported improved progression-free survival (PFS) in patients with ovarian …

Angiogenesis as a target for the treatment of ovarian cancer.

D Shaw, A Clamp, GC Jayson - Current Opinion in Oncology, 2013 - europepmc.org
Both the first-line trials stopped maintenance bevacizumab after 12 and 15 months,
respectively; yet, current data suggest that maintenance therapy should continue at least …

Angiogenesis as a target for the treatment of ovarian cancer

D Shaw, A Clamp, GC Jayson - Current opinion in …, 2013 - research.manchester.ac.uk
PURPOSE OF REVIEW: Angiogenesis has been validated as a target in ovarian cancer
through four randomized trials that have reported improved progression-free survival (PFS) …

Angiogenesis as a target for the treatment of ovarian cancer

D Shaw, A Clamp, GC Jayson - Current opinion in …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose of review Angiogenesis has been validated as a target in ovarian cancer through
four randomized trials that have reported improved progression-free survival (PFS) in …